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range from 5 to 45 with domains ranging from 2 to 8. Quality of
life was assessed by most instruments on the basis of physical
disability such as the MIDAS and MIGSEV. However, instru-
ments such as HDI and MSQOL have also included emotional
disability in the assessment of quality of life. Cronbach’s alpha of
reported ranged from 0.77 to 0.9 and one or more validities was
established in all instruments. CONCLUSION: Although all
instruments claim to assess the quality of life of patients, not all
include physical and emotional functions. The MSQ seems most
complete in this aspect, considering the psychometric properties
that are reported. In the future, instruments assessing response to
therapy should include domains measuring emotional and physi-
cal disability to improve treatment schedules.
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OBJECTIVE: Use of the EQ-5D in an insomnia population has
not been reported before. METHODS: Primary care patients (18
to 64 years of age) in a large hospital outpatient clinic were
mailed a survey packet containing EQ-5D, Insomnia Severity
Index (ISI), and MOS Short Form 36 (SF-36). Patients were
selected based on visit(s) to the clinic in the past six months and
grouped into one of the following ﬁve groups: cardiovascular
(CVD), diabetes (D), gastrointestinal (GI), musculoskeletal (MS),
and obstructive airways diseases (OAD) based on presence of
diagnostic codes related to these chronic conditions in their
medical records. RESULTS: Of 2,190 surveys mailed, 1,020
responses were received. After controlling for the relevant poten-
tial confounders, mean EQ-5D scores (i.e., average health state
utilities) for patients with insomnia were 0.68 in cardiovascular
group, 0.69 in diabetes group, 0.54 in musculoskeletal group,
0.75 in obstructive airways diseases group, and 0.61 in patients
with gastrointestinal disorders. Utilities in patients, who did not
screen positive for insomnia in the above groups, were 0.81,
0.82, 0.72, 0.83, and 0.83, respectively. Utilities for health states
experienced by patients with severe insomnia were the lowest,
with progressively higher scores in patients with milder insom-
nia, and no insomnia. Correlations between EQ-5D mobility and
SF-36 physical function domains, and SF-36 social functioning
domains were -0.64 and -0.49, respectively; between EQ-5D
pain/discomfort and bodily pain and physical functioning
domains of the SF-36 were -0.70 and -0.57, respectively;
between EQ-5D anxiety/depression and the SF-36 mental health
and vitality domains were -0.71 and -0.58, and between
EQ-5DVAS and the SF-36 general health domain was 0.74.
CONCLUSION: EQ-5D utilities in the insomnia and
no-insomnia groups, and the direction and strength of correla-
tions with the SF-36 domains were as hypothesized thereby
assuring satisfactory psychometric performance of the EQ-5D
and conﬁrming its usefulness for studying utilities in an insomnia
population.
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OBJECTIVE: To understand the association between insomnia
and HRQoL after statistically controlling for socio-
demographic characteristics, health habits, BMI, a number of
medical conditions, and the presence of depressive symptoms.
METHODS: A sample of primary care patients (18 to 64 years
of age) in a large hospital outpatient clinic was mailed a survey
packet that contained the MOS Short Form 36 (SF-36), and
Insomnia Severity Index (ISI). These patients were selected
based on their visit(s) to the clinic in the past six months and
grouped into one of the following ﬁve groups: cardiovascular
(CVD), diabetes (D), gastrointestinal (GI), musculoskeletal
(MS), and obstructive airways diseases (OAD) based on the
presence of diagnostic codes related to these chronic conditions
in their medical records. Group differences in SF-36 domain
scores were analyzed using ANOVA techniques. RESULTS:
Based on 1,020 responses (46.58% response rate), in patients
with insomnia, mean SF-36 Physical Component Summary
(PCS) scores were: CVD: 37.8 + 2.9; D: 37.6 + 3.9; GI:
45.3 + 2.9; MS: 32.4 + 3.2; OAD: 44.6 + 3.2. Mean Mental
Component Summary (MCS) scores were: CVD: 39.2 + 2.6; D:
42.7 + 4.0; GI: 33.9 + 3.8; MS: 41.1 + 3.6; OAD: 41.1 + 3.8. In
patients without insomnia PCS scores were: CVD: 47.0 + 2.4;
D: 46.4 + 3.3; GI: 49.2 + 2.2; MS: 39.9 + 3.0; OAD: 51.7 +
2.9. In the same patients MCS scores were CVD: 47.5 + 2.1; D:
47.0 + 3.3; GI: 50.0 + 2.9; MS: 50.0 + 3.4; OAD: 45.0 + 3.4. In
addition, SF-36 scores for all individual domains in patients
with insomnia were lower than those of patients without
insomnia across all disease groups. CONCLUSION: A signiﬁ-
cant independent relationship between insomnia and HRQoL
remained even after controlling for all relevant potential con-
founders. No domain of HRQoL was disproportionately inﬂu-
enced by insomnia.
PND32
DETERMINATION OFTHE LONGITUDINALVALIDITY AND
MINIMALLY IMPORTANT DIFFERENCE OFTHE 8-ITEM
PARKINSON’S DISEASE QUESTIONNAIRE (PDQ-8)
Zhao YJ1,Tan LC2, Lau PN2,Au WL2, Li SC3, Luo N4
1National University of Singapore, Singapore, Singapore, Singapore,
2National Neuroscience Institute, Singapore, Singapore, 3University of
Newcastle, Callaghan, NSW, Australia, 4National University of
Singapore, Singapore, Singapore
OBJECTIVE: This study was carried out to determine the
responsiveness, test-retest reliability and the minimally impor-
tant difference (MID) of the 8-item Parkinson’s disease Ques-
tionnaire (PDQ-8) in Asians with Parkinson’s disease (PD) in
Singapore. METHODS: A convenience sample of PD patients
attending a tertiary neuroscience clinic in Singapore completed
the English or Chinese version of PDQ-8 twice during two dif-
ferent clinic visits. On the second visit, patients also rated
changes in their health in general, their PD severity, and the
overall impact of PD on their life using a 5-point response scale
(i.e., a lot better, a little bit better, about the same, a little bit
worse, and a lot worse). RESULTS: A total of 98 patients par-
ticipated in the study. For patients who reported better condi-
tions in the second visit, Cohen’s effect size, standardized
response mean and responsiveness statistic ranged from 0.21 to
0.58; for patients who experienced worse conditions, the
responsiveness index values ranged from 0.24 to 0.68. The
intra-class correlation coefﬁcient calculated using stable patients
ranged from 0.64 to 0.76. MID values estimated using the
anchor-based method ranged from 5.8 to 7.4. CONCLUSION:
The PDQ-8 instrument is longitudinally valid in Singaporean
patients with PD. The MIDs estimated in the study can be used
for sample size calculation and interpretation of treatment ben-
eﬁts in clinical trials where the PDQ-8 summary index is used
as the primary outcome measure.
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